» Articles » PMID: 28396217

Mathematical Models of Cell Phenotype Regulation and Reprogramming: Make Cancer Cells Sensitive Again!

Overview
Publisher Elsevier
Date 2017 Apr 12
PMID 28396217
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

A cell's phenotype is the observable actualization of complex interactions between its genome, epigenome, and local environment. While traditional views in cancer have held that cellular and tumor phenotypes are largely functions of genomic instability, increasing attention has recently been given to epigenetic and microenvironmental influences. Such non-genetic factors allow cancer cells to experience intrinsic diversity and plasticity, and at the tumor level can result in phenotypic heterogeneity and treatment evasion. In 2006, Takahashi and Yamanaka exploited the epigenome's plasticity by "reprogramming" differentiated cells into a pluripotent state by inducing expression of a cocktail of four transcription factors. Recent advances in cancer biology have shown not only that cellular reprogramming is possible for malignant cells, but it may provide a foundation for future therapies. Nevertheless, cell reprogramming experiments are frequently plagued by low efficiency, activation of aberrant transcriptional programs, instability, and often rely on expertise gathered from systems which may not translate directly to cancer. Here, we review a theoretical framework tracing back to Waddington's epigenetic landscape which may be used to derive quantitative and qualitative understanding of cellular reprogramming. Implications for tumor heterogeneity, evolution and adaptation are discussed in the context of designing new treatments to re-sensitize recalcitrant tumors. This article is part of a Special Issue entitled: Evolutionary principles - heterogeneity in cancer?, edited by Dr. Robert A. Gatenby.

Citing Articles

The landscape of cell lineage tracing.

Feng Y, Liu G, Li H, Cheng L Sci China Life Sci. 2025; .

PMID: 40035969 DOI: 10.1007/s11427-024-2751-6.


Metabolic Objectives and Trade-Offs: Inference and Applications.

Lin D, Khattar S, Chandrasekaran S Metabolites. 2025; 15(2).

PMID: 39997726 PMC: 11857637. DOI: 10.3390/metabo15020101.


Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia.

Pino J, Posso C, Joshi S, Nestor M, Moon J, Hansen J Cell Rep Med. 2024; 5(1):101359.

PMID: 38232702 PMC: 10829797. DOI: 10.1016/j.xcrm.2023.101359.


Quantifying cancer cell plasticity with gene regulatory networks and single-cell dynamics.

Groves S, Quaranta V Front Netw Physiol. 2023; 3:1225736.

PMID: 37731743 PMC: 10507267. DOI: 10.3389/fnetp.2023.1225736.


Scales of Cancer Evolution: Selfish Genome or Cooperating Cells?.

Brutovsky B Cancers (Basel). 2022; 14(13).

PMID: 35805025 PMC: 9264996. DOI: 10.3390/cancers14133253.


References
1.
Takahashi K, Yamanaka S . Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126(4):663-76. DOI: 10.1016/j.cell.2006.07.024. View

2.
Udyavar A, Wooten D, Hoeksema M, Bansal M, Califano A, Estrada L . Novel Hybrid Phenotype Revealed in Small Cell Lung Cancer by a Transcription Factor Network Model That Can Explain Tumor Heterogeneity. Cancer Res. 2016; 77(5):1063-1074. PMC: 5532541. DOI: 10.1158/0008-5472.CAN-16-1467. View

3.
Cherry A, Daley G . Reprogramming cellular identity for regenerative medicine. Cell. 2012; 148(6):1110-22. PMC: 3354575. DOI: 10.1016/j.cell.2012.02.031. View

4.
Gilbert S . Developmental Plasticity and Developmental Symbiosis: The Return of Eco-Devo. Curr Top Dev Biol. 2016; 116:415-33. DOI: 10.1016/bs.ctdb.2015.12.006. View

5.
Huang S . Reprogramming cell fates: reconciling rarity with robustness. Bioessays. 2009; 31(5):546-60. DOI: 10.1002/bies.200800189. View